Neurim Pharmaceuticals ("Neurim") announces that the European Commission has approved the extension of the indication to include the treatment of insomnia in children with attention deficit ...

Syncromune ® Inc., a clinical-stage biopharmaceutical company developing SYNC-T, an in situ personalized immunotherapy platform optimized for solid tumor cancers, today announced the appointment of ...

GSK’s application is underpinned by the positive outcomes from the Phase III MATINEE trial, which demonstrated a significant ...

Kneat's SaaS model automates validation processes in pharma and biotech, reducing errors and ensuring compliance. Learn why ...

EUR/USD has shed weight for four straight trading days, declining from it’s latest swing high into 1.0950. Fiber is testing ...

GSK plc GSK announced that the European Medicines Agency (“EMA”) has accepted for review a regulatory filing, seeking ...

Bitcoin stalls near $85K as investor focus shifts to Bitcoin Act progress, ETF inflows, and macro risks including tariffs and ...

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March ...

Beyond Supply Chain: AI-Powered Innovations for Trial Optimization Alongside Clinical Supply Chain On Demand, Good AI and Intrinseque Health are introducing AI-powered solutions for protocol ...

To avoid overlaps, the industry is calling for aligning MDR/IVDR with the EU's digital frameworks, pharmaceutical regulations ...

March 24, 2025 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it is responding to the chikungunya outbreak that is rapidly ...